PLIANT THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
PLIANT THERAPEUTICS, INC. (PLRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-11
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-06-30 was 0.00%.
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-06-30 was 0.00%.
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- PLIANT THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-11 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-03 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-02-27 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-09 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-01 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-11 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |